Eli Lilly Says It Was Questioned on Pricing

Eli Lilly & Co. said in a filing that it has received a subpoena from Massachusetts officials relating to Medicaid reimbursement for the company’s products, the latest of several major drug makers to be investigated for federal pricing practices. Indianapolis-based Eli Lilly said in its quarterly financial filing with the Securities and Exchange Commission that it received a subpoena from the Massachusetts attorney general’s office in March and does not believe it broke the law.

The company did not specify which of its products were in question. A company official was not available for comment. However, the firm acknowledged in the filing that it believes “it is not the only pharmaceutical company to receive such a request.” Officials from the attorney general’s office also were not available to comment. Shares of Eli Lilly closed up 36 cents at $84.80 on the NYSE.